2 Incredibly Cheap Dividend Stocks to Buy Now

Why It Matters

High‑yield, low‑multiple stocks like EPD and BMY provide income‑focused investors with defensive exposure while offering upside potential as markets re‑price sector fundamentals.

Key Takeaways

• Enterprise Products yields ~6% dividend, forward P/E ~13
• Midstream energy offers stable cash flow, supports dividend growth
• Bristol Myers trades below 10 forward P/E, 4.2% yield
• Pharma transformation hinges on Opdivo growth, offsetting legacy decline
• Both stocks appear undervalued versus S&P 500 averages

Pulse Analysis

Dividend‑focused investors constantly seek the sweet spot where yield, valuation, and sustainability intersect. In a low‑interest‑rate environment, a 5‑6% payout from a mid‑stream energy firm like Enterprise Products Partners stands out, especially when its forward price‑to‑earnings ratio hovers in the low‑teens. The sector’s reliance on long‑term transportation contracts cushions earnings from commodity price swings, delivering predictable cash flow that can fund both capital expansion and steady dividend growth. This defensive profile makes EPD an attractive hedge against market volatility while still offering upside as infrastructure spending accelerates.

Enterprise Products’ balance sheet reflects a robust operating model: net margins above 10% and cash flow sufficient to support $2.5‑$2.9 billion of annual capital expenditures. These investments aim to broaden its fee‑based revenue base, targeting higher‑margin assets such as deep‑water terminals and storage facilities. However, investors should monitor regulatory risk, exposure to natural‑gas price fluctuations, and the company’s leverage levels, which can amplify earnings volatility during macro‑economic downturns. The forward P/E of roughly 13 suggests the market has begun to price in these risks, yet the stock remains considerably cheaper than the S&P 500 average, offering a margin of safety for income seekers.

Bristol Myers Squibb illustrates how a legacy pharmaceutical giant can reinvent its dividend narrative through pipeline innovation. While blockbuster drugs Revlimid and Eliquis face patent expirations, the firm’s oncology franchise—anchored by Opdivo—delivered a 16% year‑over‑year revenue surge in Q4 2025. This growth underpins a 4.2% dividend and a forward P/E under 10, positioning BMY as a rare cheap‑priced pharma stock with a solid yield. Investors must weigh the risk of ongoing R&D expenditures against the potential of new approvals, but the company’s strong gross margin (over 65%) and disciplined capital allocation suggest dividend sustainability. In a sector where many peers trade at premium multiples, BMY offers a compelling blend of income and upside for long‑term portfolios.